Research · Sep 3, 2026
SNDX: FY25 Deep Dive
Syndax Pharmaceuticals FY25 at $172M. NI $-285M; EPS $-3.30.
SNDX
Syndax Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$20.56
−0.58%Research · Aug 25, 2026
Menin Inhibitor Use Shifts Toward Off-Label Combination Regimens
Kura and Syndax each report about 40% of menin inhibitor use in physician-led combinations, moving the revenue variable to treatment duration rather than the label.